Home/Pipeline/GLY-200

GLY-200

Obesity

Phase 2Active

Key Facts

Indication

Obesity

Phase

Phase 2

Status

Active

Company

Glyscend Therapeutics

About Glyscend Therapeutics

Glyscend Therapeutics is pioneering a novel, non-invasive approach to treating metabolic diseases by orally administering polymers that form a temporary coating in the duodenum, mimicking the duodenal exclusion mechanism of gastric bypass surgery. The company's lead candidate, GLY-200, is in Phase 2 trials for obesity, with potential applications in type 2 diabetes and NAFLD/NASH. Backed by venture capital and led by a team with deep experience in metabolic drug development, Glyscend aims to offer a safe, effective, and accessible alternative to invasive surgical procedures for a massive global patient population.

View full company profile

Therapeutic Areas

Metabolic Gastrointestinal

Other Obesity Drugs

Drug	Company	Phase	Status
LET003	Harbour BioMed	Discovery	Active (Global)
LET001	Harbour BioMed	Discovery	Active (Global)
Obesity Target Discovery Collaboration	Fauna Bio	Target Discovery/Preclinical	Active
GLP-1 variants	Heligenics	Discovery	Active
MYO Platform (Metabolic Disease)	Renbio	Pre-clinical	Active
Obesity Clinical Trials	IMA Clinical Research	Not Applicable (Service)	Active
KAYO-2000	KayoThera	Preclinical	Active
MVD-1 (SANA)	Eolo Pharma	Phase 1	Active
GIP-neutralizing antibody	Helicore Biopharma	Pre-clinical	Active
Antral Gastroplasty / Endoscopic Sleeve	Endo-TAGSS	Pre-clinical	Active
Undisclosed siRNA Programs	Moonwalk Biosciences	Pre-clinical	Active
VIAL-INHBE (siRNA)	VIAL Dermatology CRO	Phase 1	Active